Cytokinetics (CYTK)
NASDAQ: CYTK
· Real-Time Price · USD
58.96
-3.84 (-6.11%)
At close: Oct 16, 2025, 3:59 PM
58.70
-0.44%
After-hours: Oct 16, 2025, 07:56 PM EDT
-6.11% (1D)
| Bid | 58.2 |
| Market Cap | 7.05B |
| Revenue (ttm) | 85.74M |
| Net Income (ttm) | -606.31M |
| EPS (ttm) | -5.12 |
| PE Ratio (ttm) | -11.52 |
| Forward PE | -10.74 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 61.57 |
| Volume | 2,080,201 |
| Avg. Volume (20D) | 2,167,242 |
| Open | 62.94 |
| Previous Close | 62.80 |
| Day's Range | 58.40 - 63.58 |
| 52-Week Range | 29.31 - 63.86 |
| Beta | 0.68 |
| Ex-Dividend Date | n/a |
About CYTK
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CYTK
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CYTK stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsCytokinetics is scheduled to release its earnings on
Nov 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+6.44%
Cytokinetics shares are trading higher after Barcl...
Unlock content with
Pro Subscription
2 weeks ago
+6.92%
Cytokinetics shares are trading higher. HC Wainwright & Co. reiterated its Buy rating on the stock and maintained its $120 price target.
4 weeks ago · businesswire.com
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES--(BUSINESS WIRE)---- $CYTK--CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm.
